CD44v4在乳腺浸润性导管癌中的表达及其与浸润转移的关系(1)
摘要：目的 探讨CD44v4在浸润性乳腺导管癌中的表达及其与浸润转移的关系。方法 选取2011年1月～2018年3月我院收治的乳腺浸润性导管癌185例设为观察组，另选取同期收治的乳腺良性疾病患者60例设为对照组，采用免疫组化法检测两组CD44v4的表达情况，并比较观察组CD44v4表达及临床病理因素情况。结果 观察组CD44v4阳性表达率为60.54%，高于对照组的5.00%，差异有统计学意义(P<0.05)。CD44v4表达在不同年龄、绝经前后月经状况、原发瘤大小间比较，差异无统计学意义(P>0.05);不同TNM分期、组织学分级、淋巴结转移患者的CD44v4表达比较，差异有统计学意义(P<0.05)。结论 CD44v4蛋白在乳腺浸润性导管癌患者中为高表达，检测其表达可作为判断肿瘤预后的新指标。
关键词：浸润性乳腺癌;CD44v4;浸润转移
中图分类号：R737.9 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.11.025
, http://www.100md.com
文章编号：1006-1959(2019)11-0095-03
Abstract：Objective To investigate the expression of CD44v4 in breast invasive ductal carcinoma and its relationship with invasion and metastasis.Methods A total of 185 patients breast invasive ductal carcinoma as observation group， and 60 patients with benign breast diseasea as control group， were admitted to our hospital from January 2011 to March 2018. The immunohistochemical method was used to detect the expression of CD44v4 between two groups， and the correlation between the CD44v4 expression and clinicopathologic factors of observation group was analyzed.Results The positive rate of CD44v4 expression was 60.54%，which was higher than that 5.00% of control group， the difference was statistically significant (P<0.05). There was no statistically significant among different age， pre- and postmenopausal， different size of primary tumors with CD44v4 expression in observation group(P>0.05); there was statistically significant between CD44v4 expression and patients in different TNM stage， histological grade and lymph node metastasis(P<0.05).Conclusion CD44v4 is highly expressed in breast invasive ductal carcinoma patients， and it can be used as a new marker to judge the prognosis of breast cancer.
, 百拇医药
Key words：Breast invasive ductal carcinoma;CD44v4;Invasion and metastasis
乳腺癌(breast cancer)是我国女性常见恶性肿瘤，上世纪90年代以来，中国乳腺癌发病率的增长速度是全球的2倍[1]。乳腺癌死亡的主要原因是肿瘤转移[2]。CD44v4是细胞黏附分子CD44家族中的一种变异体，目前发现在胃癌，膀胱癌等肿瘤中有表达，且与肿瘤的浸润、转移存在相关性[3-5]，但其在乳腺癌中的研究则较少报道。本研究主要探讨CD44v4在浸润性乳腺癌组织中的表达及其与浸润转移的关系，现报道如下。
1资料与方法
1.1一般资料 选取2011年1月～2018年3月柳州市柳铁中心医院收治的经病理确诊的乳腺浸潤性导管癌患者185例设为观察组，均为女性，年龄29～73岁，中位年龄53岁。另选取同期乳腺良性疾病患者60例设为对照组，均为女性，年龄21～68岁，中位年龄43岁。两组年龄比较，差异无统计学意义(P>0.05)，可比较。本研究经医院伦理委员会审批通过。, 百拇医药(李俊 李春英)
关键词：浸润性乳腺癌;CD44v4;浸润转移
中图分类号：R737.9 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.11.025
, http://www.100md.com
文章编号：1006-1959(2019)11-0095-03
Abstract：Objective To investigate the expression of CD44v4 in breast invasive ductal carcinoma and its relationship with invasion and metastasis.Methods A total of 185 patients breast invasive ductal carcinoma as observation group， and 60 patients with benign breast diseasea as control group， were admitted to our hospital from January 2011 to March 2018. The immunohistochemical method was used to detect the expression of CD44v4 between two groups， and the correlation between the CD44v4 expression and clinicopathologic factors of observation group was analyzed.Results The positive rate of CD44v4 expression was 60.54%，which was higher than that 5.00% of control group， the difference was statistically significant (P<0.05). There was no statistically significant among different age， pre- and postmenopausal， different size of primary tumors with CD44v4 expression in observation group(P>0.05); there was statistically significant between CD44v4 expression and patients in different TNM stage， histological grade and lymph node metastasis(P<0.05).Conclusion CD44v4 is highly expressed in breast invasive ductal carcinoma patients， and it can be used as a new marker to judge the prognosis of breast cancer.
, 百拇医药
Key words：Breast invasive ductal carcinoma;CD44v4;Invasion and metastasis
乳腺癌(breast cancer)是我国女性常见恶性肿瘤，上世纪90年代以来，中国乳腺癌发病率的增长速度是全球的2倍[1]。乳腺癌死亡的主要原因是肿瘤转移[2]。CD44v4是细胞黏附分子CD44家族中的一种变异体，目前发现在胃癌，膀胱癌等肿瘤中有表达，且与肿瘤的浸润、转移存在相关性[3-5]，但其在乳腺癌中的研究则较少报道。本研究主要探讨CD44v4在浸润性乳腺癌组织中的表达及其与浸润转移的关系，现报道如下。
1资料与方法
1.1一般资料 选取2011年1月～2018年3月柳州市柳铁中心医院收治的经病理确诊的乳腺浸潤性导管癌患者185例设为观察组，均为女性，年龄29～73岁，中位年龄53岁。另选取同期乳腺良性疾病患者60例设为对照组，均为女性，年龄21～68岁，中位年龄43岁。两组年龄比较，差异无统计学意义(P>0.05)，可比较。本研究经医院伦理委员会审批通过。, 百拇医药(李俊 李春英)